Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05354557 · ClinicalTrials.gov registry record · Phase 2

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)

A Phase 2 study of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
16
Enrollment target
8
Study locations

NCT05354557: Active Phase 2 study of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT05354557 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 16 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05354557, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
16 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maintenance therapy. Patients will receive iberdomide treatment beyond 12 months if they continue to derive benefit from the treatment and will continue until progression of disease or unacceptable toxicity. Follow-up will be as per standard of care for a patient on maintenance therapy, and patients will not require additional research samples.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Iberdomide

Study Locations (8)

New York

  • Memorial Sloan Kettering Suffolk-Commack (Consent and Follow up) - Commack
  • Memorial Sloan Kettering Westchester (Consent and Follow Up) - Harrison
  • Weill Cornell Medical College (Data Collection Only) - New York
  • Memorial Sloan Kettering Cancer Center (All protocol activities) - New York
  • Memorial Sloan Kettering Nassau (Consent and Followup) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Consent and Followup) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Consent and Follow-Up only) - Middletown
  • Memorial Sloan Kettering Bergen (Consent and Follow up) - Montvale

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2022-04-26
Est. Completion 2026-04-26
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05354557

The ClinicalTrials.gov registry entry for NCT05354557 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Iberdomide is the first listed.

NCT05354557 reports 8 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT05354557 about?

NCT05354557 is a clinical study titled "Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)". The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maintenance therapy. Patients will receive iberdomide ...

What is the current status of trial NCT05354557?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2022-04-26. Estimated completion is 2026-04-26.

What conditions does trial NCT05354557 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05354557?

The interventions under investigation include: Iberdomide (DRUG).

Who is sponsoring clinical trial NCT05354557?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05354557 being conducted?

This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.